TIDMGENI
RNS Number : 0495Y
GENinCode PLC
28 December 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED
STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR
ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO
ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR
BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK
MAR").
28 December 2023
GENinCode Plc
("GENinCode" or the "Company")
Result of Retail Offer
Further to the announcement dated 21 December 2023, GENinCode
plc (AIM: GENI), the polygenics company focused on the prevention
of cardiovascular disease ("CVD"), is pleased to announce that,
following the closing of the Retail Offer on the BookBuild platform
on 27 December 2023, 1,147,560 Ordinary Shares will be issued at
the Issue Price of 5 pence per Retail Offer Share in connection
with the Retail Offer, raising an additional GBP57,378.
Consequently, conditional on the passing of the Resolutions at
the General Meeting, 67,576,000 Placing Shares, 12,424,000
Subscription Shares and 1,147,560 Retail Offer Shares, resulting in
a total of 81,147,560 new Ordinary Shares, will be issued in
relation to the Placing, Subscription and Retail Offer, raising
total gross proceeds of GBP4.06 million.
Admission and Total Voting Rights
Application has been made for the Retail Offer Shares to be
admitted to trading on AIM ("Admission"). Admission is expected to
take place at 8.00 a.m. on or around 10 January 2024.
The Retail Offer Shares will, when issued, be credited as fully
paid up and will have the same rights as the Existing Ordinary
Shares including, voting, dividend, return of capital and other
rights, and will on issue be free of all claims, liens, charges,
encumbrances and equities.
Following Admission, the total number of Ordinary Shares in the
capital of the Company in issue will be 176,964,426 with each
Ordinary Share carrying the right to one vote. There are no shares
held in treasury and therefore, following Admission, the total
number of voting rights in the Company will be 176,964,426. The
above figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure, Guidance
and Transparency Rules.
Capitalised terms used in this announcement have the meaning
given to them in the Placing and Retail Offer announcement dated 21
December 2023, unless otherwise defined in this announcement.
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook
PR
Matthew Walls, CEO
Cavendish Capital Markets Limited Tel: +44 (0)20 7220 0500
Giles Balleny/ Dan Hodkinson (Corporate Finance)
Nigel Birks (ECM)
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or
Anna Dunphy / Louis Ashe-Jepson geincode@walbrookpr.com
/ Mob: +44 (0)7876 741 001 /
Phillip Marriage +44 (0)7747 515 393 / +44 (0)
7867 984 082
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through
GENinCode S.L.U, and in the United States through GENinCode U.S.
Inc.
GENinCode predictive technology provides patients and physicians
with globally leading preventive care and treatment strategies.
GENinCode genetic tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment for
coronary heart disease.
About Cardiovascular Disease (CVD):
Heart and circulatory disease also known as cardiovascular
disease (CVD) is the leading cause of death globally, taking an
estimated 17.9 million lives each year, with Coronary Heart Disease
(CHD) representing the leading cause of death for men, women, and
people of most racial and ethnic groups in the United States. CVD
is a group of disorders of the heart and blood vessels that include
coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths
are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age. By 2030 the
global cost of CVD is set to rise from approximately US$863 billion
in 2010 to US$1,044 billion and is both a major health issue and
global economic burden.
Cardiovascular disease, causes a quarter of all deaths in the UK
and is the largest cause of premature mortality in deprived areas
and is the single biggest area where the NHS can save lives over
the next 10 years. CVD is largely preventable, through lifestyle
changes and a combination of public health and action on smoking
and tobacco addiction, obesity, tackling alcohol misuse and food
reformulation.
The most important behavioural risk factors of heart disease and
stroke are unhealthy diet, physical inactivity, tobacco use and
harmful use of alcohol. The effects of behavioural risk factors may
show up in individuals as raised blood pressure, raised blood
glucose, raised blood lipids, and overweight and obesity. These
"intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke,
heart failure and other complications.
Identifying those at highest risk of CVDs and ensuring they
receive appropriate treatment can prevent premature deaths. Access
to noncommunicable disease medicines and basic health technologies
in all primary health care facilities is essential to ensure that
those in need receive treatment and counselling.
The current standard of care for assessing cardiovascular risk
is primarily based on traditional clinical risk factors such as
age, sex, smoking, body mass, blood pressure and cholesterol levels
from which individuals are categorised as being at low, moderate or
high risk of a CVD event. This categorisation is imperfect as CVD
events frequently occur in those thought to be at low or moderate
risk. The size of the populations at low or moderate risk are much
larger than those at high or very high risk so whilst the relative
risk of a CVD event may be small, the absolute number of CVD events
in low and moderate risk populations is much greater than the
number of events in higher risk categories.
Clinicians have for many years recognised the importance of
prior CVD events within the families of their patients because
genetic factors contribute to the development of atherosclerosis
and a patient's family history has become a surrogate for their
inherited genetic risk. In recent years, with the advances of
genomics, it has proved possible to add genetic profiling to
conventional CVD risk factors, the combination of the two (genetics
and conventional clinical risk factors) enhancing the predictive
capability of patient risk thereby resulting in a personalised and
preventive approach to CVD.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEQVLBLXLLZFBD
(END) Dow Jones Newswires
December 28, 2023 02:00 ET (07:00 GMT)
Grafico Azioni Genincode (LSE:GENI)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Genincode (LSE:GENI)
Storico
Da Nov 2023 a Nov 2024
